Home › NCT06502158
Mifepristone vs Misoprostol
Mifepristone Versus Misoprostol for Cervical Preparation Prior to Procedural Abortion at 12 to 16 Weeks' Gestation in an Academic Medical Center: a Randomized Controlled Pilot Trial
Who can join
Ages 18 to 45 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * English or Spanish-speaking * Capacity to consent * Seeking induced abortion of a singleton pregnancy between 12 weeks, 0 days and 16 weeks, 6 days (based on age at day of surgery) Exclusion Criteria: * History of more than two prior Cesarean deliveries * Sonographic evidence of placenta previa * Sonographic concern for morbidly adherent placenta * Prior obstetric hemorrhage requiring transfusion * Obstructive cervical or lower uterine segment fibroid * Current therapeutic anticoagulation use * Cerclage in situ * History of more than one prior cervical excisional procedure * BMI greater than 50 kg/m\^2
About the study
The Investigator team hypothesizes that in a randomized trial comparing mifepristone-alone or misoprostol-alone for cervical preparation for procedural abortions at 12 to 16 weeks in hospital-based care, the proportion of patients who achieve successful cervical dilation will be different between the study groups.
What is being tested
- Mifepristone (drug)
- Misoprostol (drug)
Sponsor: Montefiore Medical Center · Participants: 94 · Started: Oct 31, 2024
Contact the study team
- Laura Fletcher, MD, MPH · Phone: 516-587-3297
- Antoinette Danvers, MD, MSCR, MBA · Phone: 718-405-8260
Official record on ClinicalTrials.gov — NCT06502158
Locations in the U.S.
| New York | Montefiore Medical Center, The Bronx |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.